Hexamethylmelamine as a Single Second-Line Agent in Ovarian Cancer: Follow-up Report and Review of the Literature

Neurological complications of chemotherapy to the central nervous system

“…Hexamethylmelamine is an alkylating agent that is used mainly as second-line therapy for recurrent ovarian cancer (Manetta et al, 1997). Although the drug does not cross the BBB very well, its metabolites can readily enter the CNS.…”

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

“…One research alternative to this approach is to delay or prevent disease recurrence with consolidation therapy that uses one or more of the multiple chemotherapeutic agents known to be active in recurrent disease ( 7,8 ) . One such agent, altretamine, has been used in the treatment of recurrent ovarian cancer for many years, is well tolerated, and is orally administered ( 9–13 ) . Like most agents used in the treatment of ovarian cancer, altretamine has proven to be more active in the treatment of platinum‐sensitive than platinum‐resistant disease ( 9–13 ) .…”

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

“…One research alternative to this approach is to delay or prevent disease recurrence with consolidation therapy that uses one or more of the multiple chemotherapeutic agents known to be active in recurrent disease (7,8) . One such agent, altretamine, has been used in the treatment of recurrent ovarian cancer for many years, is well tolerated, and is orally administered (9)(10)(11)(12)(13) . Like most agents used in the treatment of ovarian cancer, altretamine has proven to be more active in the treatment of platinumsensitive than platinum-resistant disease (9)(10)(11)(12)(13) .…”